The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.

6533b85bfe1ef96bd12bb4ec

RESEARCH PRODUCT

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.

Marat V. Ezhov Angela Pirillo Lars Ellegård Andrea Poli Günter Silbernagel Günter Silbernagel Olivier S. Descamps György Paragh Demosthenes B. Panagiotakos Alberico L. Catapano Maciej Banach Maciej Banach Maciej Banach Daniel Pella Michal Vrablík Zlatko Fras Petri T. Kovanen Bernhard Föger Eric Bruckert Eric Bruckert ŽEljko Reiner Winfried März Winfried März Winfried März Margus Viigimaa Gustavs Latkovskis

subject

Gastrointestinal Diseases [SDV]Life Sciences [q-bio]Hypercholesterolemia /Self Medication 030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences Food-Drug Interactions 0302 clinical medicine Plasma cholesterol Biotransformation Double-Blind Method Chinese traditional Internal Medicine Red yeast rice Medicine Cytochrome P-450 CYP3A Humans Multicenter Studies as Topic Prodrugs 030212 general & internal medicine Lovastatin Musculoskeletal Diseases Medicine Chinese Traditional Expert Testimony ComputingMilieux_MISCELLANEOUS Biotransformation Randomized Controlled Trials as Topic Biological Products Clinical Trials as Topic Molecular Structure Ryanodine receptor business.industry General Medicine 3. Good health Cholesterol blood [SDV] Life Sciences [q-bio]Cholesterol Cardiovascular Diseases Expert opinion Dietary Supplements lipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business

description

1. Preamble : Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) [1]. Increased levels of low density lipoprotein cholesterol (LDL-C) are associated with an increased risk of coronary heart disease (CHD) and many clinical trials have shown that reducing LDL-C levels significantly reduced the CHD and CVD risk [[2], [3], [4], [5]]. Thus LDL-C-lowering is the main approach for the management of cardiovascular disease. Current guidelines suggest LDL-C levels targets based on the individual CV risk; such targets can be achieved by several means, which include both lifestyle changes and pharmacological approaches [6], with statins being the cornerstone of cardiovascular prevention. [...]

year	journal	country	edition	language
2019-12-01

10.1016/j.atherosclerosissup.2019.08.023 https://hdl.handle.net/2078.1/237001